Skip to content
Evigrade
MajorDirect thrombin inhibitor×Non-dihydropyridine calcium channel blocker

Updated · Methodology

Mechanism

Dabigatran etexilate is a substrate of the efflux transporter P-glycoprotein (P-gp), and P-gp inhibitors raise dabigatran plasma levels (dabigatran summary of product characteristics, SmPC, European Medicines Agency, EMA). Verapamil inhibits P-gp and the enzyme CYP3A4 (verapamil SmPC, Spanish Agency of Medicines and Medical Devices, AEMPS). The largest rise in dabigatran exposure came when the first dose of immediate-release verapamil was given one hour before dabigatran. Peak concentration (Cmax) then rose about 2.8-fold and the area under the concentration–time curve (AUC) about 2.5-fold (dabigatran SmPC, EMA). With extended-release verapamil, the rises were smaller, about 1.9-fold and 1.7-fold, and with multiple doses of verapamil about 1.6-fold and 1.5-fold (dabigatran SmPC, EMA). When verapamil was taken 2 hours after dabigatran, there was no significant interaction (Cmax about 1.1-fold, AUC about 1.2-fold), because dabigatran is fully absorbed by then (dabigatran SmPC, EMA).

Symptoms

Dabigatran can cause occult or overt bleeding in any tissue or organ, and severe bleeding can lead to disability or death (dabigatran summary of product characteristics, SmPC, European Medicines Agency, EMA). Common adverse reactions include nosebleeds, gastrointestinal bleeding, bleeding into the skin and genitourinary bleeding, including blood in the urine. In atrial fibrillation, anaemia is also common (dabigatran SmPC, EMA). Bleeding complications can present as weakness, pallor, dizziness, headache, unexplained swelling, shortness of breath or shock with no apparent cause (dabigatran SmPC, EMA). Concomitant verapamil and moderate renal impairment (creatinine clearance 30–50 mL/min) are among the main factors that raise dabigatran plasma levels (dabigatran SmPC, EMA).

Management

The combination is not contraindicated, but reduce the dabigatran dose. With verapamil, the recommended dose is 110 mg twice daily (220 mg a day) instead of 150 mg twice daily. This applies to adults with atrial fibrillation and to adults treated for deep vein thrombosis (DVT) and pulmonary embolism (PE) or for prevention of their recurrence. Take dabigatran and verapamil at the same time (dabigatran summary of product characteristics, SmPC, European Medicines Agency, EMA). For DVT and PE, this dose is based on pharmacokinetic and pharmacodynamic analyses and has not been studied in this clinical setting (EMA). After elective hip or knee replacement, patients taking verapamil receive a single 75 mg capsule of dabigatran on the day of surgery. They then take 150 mg once daily (two 75 mg capsules) for 10 days after knee surgery or 28–35 days after hip surgery. Take both drugs at the same time. In moderate renal impairment (creatinine clearance 30–50 mL/min), consider reducing the dose to 75 mg daily (dabigatran 110 mg SmPC, EMA). Use particular caution when combining dabigatran with verapamil, especially if bleeding occurs and when renal function is reduced (dabigatran SmPC, EMA). The verapamil SmPC asks for close clinical monitoring of the combination, especially in case of bleeding and in patients with mild to moderate renal impairment (verapamil SmPC, Spanish Agency of Medicines and Medical Devices, AEMPS). Before starting, assess renal function as creatinine clearance (Cockcroft–Gault formula). Dabigatran is contraindicated when creatinine clearance is below 30 mL/min. In patients over 75 years or with mild or moderate renal impairment, check creatinine clearance at least once a year. Check it more often if renal function may decline (dabigatran SmPC, EMA). If haemoglobin, haematocrit or blood pressure falls without explanation, look for a bleeding site. Stop dabigatran if severe bleeding occurs. In adults with life-threatening or uncontrolled bleeding, consider the specific reversal agent idarucizumab (dabigatran SmPC, EMA). According to the US dabigatran label, verapamil needs no dose change in atrial fibrillation. In DVT, PE and after hip replacement, the label says to avoid P-glycoprotein (P-gp) inhibitors in patients with creatinine clearance below 50 mL/min (dabigatran label, US Food and Drug Administration, FDA). In children, dabigatran with P-gp inhibitors has not been studied, but the risk of bleeding may rise (dabigatran SmPC, EMA).

Your whole list in one report

Up to 15 drugs: every pair in one table and a PDF report. Your first report is free: we only ask for your email

Add more drugs

Medicine list: everything you take in one place →

Sources

Other interactions with Dabigatran

Other interactions with Verapamil